<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="37480">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02618616</url>
  </required_header>
  <id_info>
    <org_study_id>ZPL389/102</org_study_id>
    <nct_id>NCT02618616</nct_id>
  </id_info>
  <brief_title>A Study to Determine the Efficacy of ZPL-3893787 in Subjects With Plaque Psoriasis</brief_title>
  <official_title>Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Determine the Efficacy, Safety and Tolerability of Once Daily Oral ZPL-3893787 (30mg) Administered for 12 Weeks in Adults With Moderate to Severe Plaque Psoriasis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ziarco Pharma Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ziarco Pharma Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a randomized, double blind, placebo controlled, parallel group study in
      approximately 120 subjects with moderate to severe psoriasis with a PASI score of at least
      10. Following run-in subjects will be randomized to receive either oral 30 mg ZPL-3893787
      once daily or placebo once daily for 12 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a randomized, double blind, placebo controlled, parallel group study in
      approximately 120 subjects with moderate to severe psoriasis with a Psoriasis Area and
      Severity Index (PASI) score of at least 10 and an Investigator's Global Assessment (IGA) of
      3 (0-4 scale). Following run-in subjects will be randomized to receive either oral 30 mg
      ZPL-3893787 once daily or placebo once daily for 12 weeks. Subjects will attend the clinic
      at Baseline (Day 0) when they will be reviewed to confirm they meet inclusion/exclusion
      criteria. If appropriate, they will be randomized to received either oral 30 mg ZPL-3893787
      once daily or placebo once daily for 12 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage change from baseline in PASI score</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in IGA</measure>
    <time_frame>Week 12</time_frame>
    <description>Reduction of at least 2 categories</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">129</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>ZPL-3893787</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZPL-3893787 30 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched placebo once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZPL-3893787</intervention_name>
    <arm_group_label>ZPL-3893787</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A documented history of moderate to severe plaque psoriasis for at least 6 months
             prior to screening.

          -  Male or female, aged ≥18 years.

          -  Psoriasis Area and Severity Index (PASI) ≥10 at both Screening and Day 0.

          -  An Investigator's Global Assessment (IGA) score ≥ 3 at both Screening and Day 0.

          -  Psoriasis affecting ≥10% BSA at Screening and Day 0.

        Exclusion Criteria:

          -  Current diagnosis of Pustular, Guttate, Erythrodermic, exfoliative or only nail
             psoriasis or a diagnosis of inverse psoriasis without having plaque psoriasis.

          -  Concurrent skin disease (e.g. acne) of such severity in the study area that it could
             interfere with the study evaluation or presence of skin comorbidities that may
             interfere with study assessments.

          -  Active skin infections (e.g. impetigo, abscesses) or any other clinically apparent
             infections.

          -  Biologic treatments for psoriasis (e.g. Enbrel, Humira, Stelara, Cosentyx) within 3
             months of the start of the Run-In.

          -  Phototherapy (e.g. UVA, UVB, PUVA) within 4 weeks of the start of the Run-In.

          -  Oral calcineurin inhibitors and immunosuppressants (e.g. cyclosporine, azathioprine,
             methotrexate) within 4 weeks of the start of the Run-In.

          -  Systemic corticosteroids within 4 weeks of the start of the Run-In.

          -  Oral antihistamines and leukotriene inhibitors and tricyclic antidepressants within 1
             week of the start of the Run-In.

          -  Topical steroids (any potency), topical calcineurin inhibitors (tacrolimus,
             pimecrolimus), salicylic acid and urea containing treatments and coaltar
             preparations, topical and oral retinoids and vitamin D derivatives, within 1 week of
             the start of the Run-In.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lynn Purkins</last_name>
    <role>Study Director</role>
    <affiliation>Ziarco Pharma Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>US Study Centre</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>3608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US Study Centre</name>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <zip>Fl 34744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bulgarian Study Centre</name>
      <address>
        <city>Montana</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bulgarian Study Centre</name>
      <address>
        <city>Pleven</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bulgarian Study Centre 2</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bulgarian Study Centre</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bulgarian Study Centre</name>
      <address>
        <city>Tarnovo</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bulgarian Study Centre</name>
      <address>
        <city>Varna</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polish Study Centre</name>
      <address>
        <city>Czestochowa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polish Study Centre</name>
      <address>
        <city>Elbląg</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polish Study Centre</name>
      <address>
        <city>Karczew</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polish Study Centre</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polish Study Centre</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polish Study Centre</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polish Study Centre</name>
      <address>
        <city>Toruń</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UK Study Centre</name>
      <address>
        <city>Blackpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UK Study Centre</name>
      <address>
        <city>Cannock</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UK Study Centre</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UK Study Centre</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Poland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 23, 2017</lastchanged_date>
  <firstreceived_date>November 27, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
